Societe Generale's asset manager Lyxor has delayed the launch of its Healthcare Opportunity Capital Guaranteed Fund.
The 3.5-year product, which was due to be launched last month, offering an income linked to a basket of six shares (Johnson & Johnson, Merck, Astellas Pharma, Schering-Plough, Boston Scientific, and Intuitive Surgical).
A source at the bank did not wish to comment on the reasons for the indefinite delayed launch of the product, and could not say when the French-registered fund, would be relaunched.
This product appears on the Singapore database.